NOVO NORDISK A/S (NVO)

Novo Nordisk is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. It develops and markets treatments for diabetes, obesity, and other chronic diseases. Its key products include Ozempic, Wegovy, Rybelsus, and insulin therapies.

TickerNVO
CompanyNOVO NORDISK A/S
ExchangeNYSE
HeadquartersBAGSVAERD DENMARK, G7

Income statement — period ending 2025-12-31

AdjustedWeightedAverageShares4,447,700,000 shares
BasicEarningsLossPerShare3 USD/shares
CostOfSales$8,900,588,500
DilutedEarningsLossPerShare3 USD/shares
GrossProfit$37,892,149,546
IncomeTaxExpenseContinuingOperations$4,255,289,181
InterestExpense$636,945,904
ProfitLoss$15,508,656,230
ProfitLossBeforeTax$19,763,945,411
ProfitLossFromOperatingActivities$19,327,606,429
ResearchAndDevelopmentExpense$7,878,780,108
Revenue$46,792,738,046
RevenueFromInterest$192,128,441
ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod$0
WeightedAverageShares4,443,000,000 shares

Sourced from SEC EDGAR/XBRL filings via StockSpectro.

View full interactive research on StockSpectro